Nutrilexic

    Dossier — Peptides

    Peptides:
    two worlds not to be confused

    A peptide is a short chain of amino acids carrying a biological message. The word covers two opposite realities.

    Authorised

    Peptide medicines

    • Insulin, semaglutide, tirzepatide
    • Phase III trials, EMA and FDA clearance
    • Prescribed, with medical follow-up
    Not authorised

    “Research” peptides

    • BPC-157, TB-500, CJC-1295
    • No authorisation, no purity control
    • Sale for human use unlawful in Europe

    Written and reviewed by Catherine Piault, naturopath · Last reviewed:

    Map of the dossier

    Tap a dot to open the exploration.

    Illustration: gut L cells release GLP-1 towards the brain and pancreas
    GLP-1 is made by the gut after every meal, then acts on the pancreas and the brain's appetite centres.
    Path 1

    How do approved GLP-1 peptides work?

    A hormone your body already makes, and the medicines that copy it.

    01

    How GLP-1 works

    The satiety hormone your gut makes after every meal — and what naturally amplifies it.

    Read

    02

    Semaglutide, tirzepatide: what the science says

    Mechanism, approved indications, STEP and SURMOUNT trial results.

    Read

    Detailed comparison with berberine: Ozempic versus berberine, in the Weight dossier.

    Path 2

    Are research peptides safe and legal?

    What the literature actually shows, and why the unregulated market is the real problem.

    Health warning

    So-called research peptides (BPC-157, CJC-1295, ipamorelin, TB-500) are not authorised for human use in Europe or the United States. This path is strictly documentary: it is not an encouragement to use, not a protocol, and not medical advice.

    BPC-157, CJC-1295, TB-500: what do we really know?

    2026 legal status, actual level of evidence, risks of an unregulated market.

    Read

    Go further

    Four related explorations

    Food, brain, mitochondria: peptides beyond the medicine.

    Living foods and peptides

    The bioactive peptides fermentation makes.

    Read

    What your plate does that Ozempic doesn't

    Seven foods that stimulate natural GLP-1.

    Read

    GLP-1 and the brain: beyond weight

    Alcohol, nicotine, depression: the reward circuits.

    Read

    Peptides and mitochondria

    MOTS-c, humanin, SS-31: the language of cellular energy.

    Read

    Frequently asked questions

    What is the difference between a peptide medicine and a wellness peptide?

    The difference is not the molecule but the regulatory road. A peptide medicine such as semaglutide has passed phase III clinical trials, obtained EMA and FDA marketing authorisation, is manufactured under pharmaceutical control and prescribed with follow-up. A wellness peptide such as BPC-157 has passed none of these stages and is sold online under a “research use only” label.

    Are all peptides banned?

    No. Several peptides are long-authorised, prescribed medicines: insulin, GLP-1 analogues (semaglutide, liraglutide), tirzepatide. It is the so-called research peptides, sold without marketing authorisation or purity control, whose sale for human use is unlawful in Europe.

    Can you raise your own peptides naturally?

    For some of them, yes. Endogenous GLP-1, for instance, is secreted by the gut in response to fibre, protein, short-chain fatty acids produced by the microbiota and certain fermented foods. This does not reproduce the pharmacological effect of an injectable analogue, but it acts on the same physiological circuit.

    Scientific sources and monthly watch

    Peptides watch — monthly update

    This dossier is reviewed monthly. Monitored each month: PubMed-indexed publications on the peptides covered, EMA and FDA communications (alerts, withdrawals, new authorisations), updates to the WADA prohibited list, and ANSM notices on products sold online. Any new data that changes a conclusion is folded into the text and added to the sources.

    Last review: · Next review due:

    Sources

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021;384:989-1002. — DOI : 10.1056/NEJMoa2032183
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022;387:205-216. — DOI : 10.1056/NEJMoa2206038
    3. European Medicines Agency — Wegovy (semaglutide), European public assessment report.
    4. European Medicines Agency — Mounjaro (tirzepatide), European public assessment report.
    5. U.S. Food and Drug Administration — Certain Bulk Drug Substances for Use in Compounding: category 2 listing (includes BPC-157).
    6. World Anti-Doping Agency — The Prohibited List: S2 Peptide Hormones, Growth Factors and Related Substances.
    7. European Medicines Agency — Register of authorised medicines (no marketing authorisation exists for BPC-157, CJC-1295, ipamorelin or TB-500).
    8. PubMed — published literature on BPC-157 (predominantly rodent and in vitro studies).
    9. PubMed — published literature on thymosin beta-4 / TB-500 in humans.
    10. ClinicalTrials.gov — registered interventional trials mentioning BPC-157.

    Written and reviewed by Catherine Piault, naturopath · Last reviewed:

    Ce site utilise des cookies et collecte des données (e-mails, progrès dans les explorations) pour améliorer votre expérience. Lire notre politique de confidentialité.